United States Surgical Corporation

Acorda Therapeutics, Inc.

Depuy Synthes Products, Inc.

Other

Affinergy Inc.

Mayo Foundation for Medical Education and Research

Synthes Usa, LLC

United States Surgical Corp. a Division of Tyco Healthcare Group

Synthes Gmbh

Elliott A Gruskin

Anthony O Caggiano

Ying Jiang

Gargi Roy

Kevin M Connolly

Steven L Bennett

Jennifer Iaci

Sarah J Kasperbauer

Guanghui Zhang

Andrea M Vecchione

Douglas D Buechter

Jack L Tseng

Robert Frigg

Sean Hamilton Kerr

Mark T Fulmer

David A Armbruster

Andrea Montali

Rohini D'Souza

Doug Buechter

Kevin Connelly

Stefan Beck

Thomas Imwinkelried

Hanne Gron

Kevin Connolly

Pearl Espino

Paul Theodore Hamilton

Moses Rodriguez

Daniel R Lee

Michael Lehmicke

Andrew R Blight

Arthur E Warrington

Shrikumar Ambujakshan Nair

Allan J Bieber

Christofer T Christoforou

Martyn Kerry Darby

Isaac Gilliam Sanford

R Edward Benson

Kurtis Wheeler

John S Bobo

Andreas Boger

Lloyd S Brown

Stephen Hornsby

Melissa Brown

Meredith Hans

Yelena G Sheptovitsky

David Duffin

Eric Walter Theodore Chojnicki

Christofer T Chistoforou

Meredith Hans-Moore

Michael P Zimber

Eric Theodore Chojnicki

Rohini D'souza

Isaac G Sanford

Roy Gargi

S J Hogan

A M Vecchione

J F Iaci

G Roy

Self-supporting inflatable grow tents include a base surface, a top surface, and a plurality of sidewalls. The sidewalls include an integrated lighting system. The inflatable grow tents include a plurality of support members configured to structurally support the grow tent when inflated, and an air circulation assembly including an air blower and a carbon filter. The grow tents include a lighting system configured to provide a standard deviation of average photosynthetic active radiation that is from about 2 to about 8 within the grow tent when the lighting system is active.

Inflatable grow tent with integrated lighting

A photobioreactor device for growing photosynthetic organisms, organisms that feed on photosynthetic organisms and hydroponics is disclosed. The device may include a lighting system integrated around the circumference of the device. In embodiments, a cap configured to seal the container has ports configured to permit passage of fluid out of or into a container without removing the cap. In some embodiments, organisms are grown in a disposable bag secured between the cap and the container.

Compact photobioreactor with built-in lights

A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood stream into tissue. The present invention provides methods of reducing penetration of cells associated with inflammation into tissue of a patient. Several methods are also provided for the regulation and suppression of inflammation comprising administering enzymes that digest chondroitin sulfates. Also provided are methods of treating and preventing inflammation associated with infection, injury and disease.

Methods of reducing extravasation of inflammatory cells

A drug-impregnated sleeve for encasing a medical implant is provided. In one embodiment, the sleeve may include a body made of a biologically-compatible material that defines an internal cavity configured to receive the medical implant. In one embodiment, the biologically-compatible material is bioresorbable. The body may include a plurality of apertures, such as perforations or holes, extending from the cavity through the body. The sleeve may further include a first end, a second end, and a drug impregnated into the resorbable sheet. In one possible embodiment, the first end of the sleeve may be open for receiving the medical implant therethrough and the second end may be closed. The implant may be encased in the sleeve and implanted into a patient from which the drug is dispensed in vivo over time to tissue surrounding the implantation site. In one embodiment, the body is made from at least one sheet of a biologically-compatible material.

Drug-impregnated encasement

A degradation controlled metal implant and methods of controlling the degradation of the implant. In one embodiment, the implant includes a body, one or more apertures, and one or more fastener blanks fixed within one or more apertures. In another embodiment, the implant includes a body of a first material and a second material plated in various patterns over the first material.

Controlling the degradation of bioresorbable metal implants

Invention embodiments described herein include methods and devices for stimulating mesenchymal stem cells in a stem cell source to differentiate into osteoblasts capable of forming bone. Devices and methods described include exposing a stem cell source, such as bone marrow aspirate, adipose tissue and/or purified allogenic stem cells, to an active agent, in a manner effective to form activated stem cells.

Method and device for activating stem cells

Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.

Compositions and methods for promoting neuronal outgrowth

Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.

Compositions and methods including a recombinant human MAB that promotes CNS remyelination

The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system ('CNS') injury or disease.

Proteoglycan degrading mutants for treatment of CNS

This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules.

Fusion proteins for the treatment of CNS

A drug-impregnated sleeve for encasing a medical implant is provided. In one embodiment, the sleeve may include a body made of a biologically-compatible material that defines an internal cavity configured to receive the medical implant. In one embodiment, the biologically-compatible material is bioresorbable. The body may include a plurality of apertures, such as perforations or holes, extending from the cavity through the body. The sleeve may further include a first end, a second end, and a drug impregnated into the resorbable sheet. In one possible embodiment, the first end of the sleeve may be open for receiving the medical implant therethrough and the second end may be closed. The implant may be encased in the sleeve and implanted into a patient from which the drug is dispensed in vivo over time to tissue surrounding the implantation site. In one embodiment, the body is made from at least one sheet of a biologically-compatible material, hi one embodiment, the sleeve may be made in least in part from caprolactone to add stretchability to the sleeve.

Growing community of inventors

Malvern, PA, United States of America

Elliott A Gruskin